Trial site
Shanghai Fourth People's Hospital
Shanghai, 200000, ChinaNot linked to an institution yet
- 15running trials
- 1closed trial
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 1/22 trials
- Phase 21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Recruiting4 trials
- Not yet recruiting3 trials
- Terminated1 trial
- Lead sponsor
- Janssen Research & Development, LLC8 trials
- Brise Pharmaceuticals Co., Ltd.2 trials
- European Myeloma Network B.V.1 trial
- Evopoint Biosciences Inc.1 trial
- Fujian Medical University Union Hospital1 trial
- and 3 more
Running trials
Not yet recruiting
Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models
NCT07897955· Fujian Medical University Union Hospital· Source
Contact: Yibin Fang
Not yet recruiting
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults
NCT07835152· Phase 3· Brise Pharmaceuticals Co., Ltd.· Source
Contact: Brise Pharmaceuticals Co., Ltd.
Recruiting
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
NCT07792681· Phase 2/3· Brise Pharmaceuticals Co., Ltd.· Source
Contact: Brise Pharmaceuticals Co., Ltd.
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· Phase 3· Evopoint Biosciences Inc.· Source
Contact: Yingjie zhao
Active, not recruiting
Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms
NCT06731946· Yibin Fang· Source
Active, not recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
NCT06049290· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: dongtao meng
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797· Phase 3· European Myeloma Network B.V.· Source
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781· Phase 4· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error